A group of senior gym-goers who got their prostates checked at roughly the same time were shocked to find almost half of them had early signs of cancer. The nine men meet regularly to work out at ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

Some readers of this column who sought access to Dr Samuel Johnson for help in respect of their ailing prostate glands, or ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Graham Dean is convinced he would not be here today to enjoy his retirement if he hadn't received an invitation through the ...

There will be about 299,010 new cases of prostate cancer diagnosed this year, according to the American Cancer Society.

Kevin P. Martin Jr. was shocked to learn he had stage 4 prostate cancer at 61. The endurance athlete has vowed to stay active ...

A team of University of Kentucky Markey Cancer Center researchers have found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug treatment.